These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37334773)

  • 21. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
    Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
    Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
    Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
    Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
    Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
    Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS;
    Biol Blood Marrow Transplant; 2018 May; 24(5):923-929. PubMed ID: 29339269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melphalan 200 mg/m
    Brioli A; Vom Hofe F; Rucci P; Ernst T; Yomade O; Hilgendorf I; Scholl S; Sayer H; Mügge LO; Hochhaus A; von Lilienfeld-Toal M
    Bone Marrow Transplant; 2021 May; 56(5):1209-1212. PubMed ID: 33299059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Y
    Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
    Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
    Vaxman I; Visram A; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Muchtar E; Kapoor P; Hogan W; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Berger T; Gertz MA
    Bone Marrow Transplant; 2021 May; 56(5):1144-1150. PubMed ID: 33273658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
    Miyamoto T; Yoshimoto G; Kamimura T; Muta T; Takashima S; Ito Y; Shiratsuchi M; Choi I; Kato K; Takenaka K; Iwasaki H; Takamatsu Y; Teshima T; Akashi K
    Int J Hematol; 2013 Sep; 98(3):337-45. PubMed ID: 23877150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
    Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
    Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
    Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.
    Ladbury C; Somlo G; Dagis A; Yang D; Armenian S; Song JY; Sahebi F; Spielberger R; Popplewell L; Parker P; Forman S; Snyder D; Rincon A; Liu A; Frankel P; Wong J
    Transplant Cell Ther; 2022 Jul; 28(7):367.e1-367.e9. PubMed ID: 35534000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
    Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
    Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
    Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.